Autogene cevumeran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

11 competitors in Transitional Cell Carcinoma

#DrugCompanyPhaseTrials

1

Eloxatin

Teva

Approved

—2

Taxol

Teva

Approved

—3

Mitosol

UUroGen Pharma Ltd.

Approved

—4

Ifex

BBaxter Healthcare Corporation

Approved

—5

Adrucil

EElorac, Inc.

Approved

—6

Opdivo

Bristol-Myers Squibb

Phase 3

37

Dato-Dxd

AstraZeneca

Phase 3

18

Rilvegostomig

AstraZeneca

Phase 3

19

Tecentriq

Roche

Preclinical

—10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1Show 1 more competitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Melanoma1 trial

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Completed·Roche·Phase 2·NCT03815058·131 enrolled

Metastatic Tumors1 trial

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed·Roche·Phase 1·NCT03289962·272 enrolled

Adenocarcinoma, Pancreatic Ductal1 trial

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma

Active, not recruiting·Roche·Phase 2·NCT05968326·260 enrolled

Transitional Cell Carcinoma1 trial

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma

Active, not recruiting·Roche·Phase 2·NCT06534983·62 enrolled

Details

Drug Info

Related News